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Summary 
Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, 
we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxin- 
induced toxicity We therefore xamined the effects of Ibl0 administration before lipopolysaccharide 
(LPS) challenge in mice. A marked reduction in the amounts of LPS-induced tumor necrosis 
factor (TNF) release in the circulation was observed after IL-10 pretreatment a doses as low 
as 10 U. Ibl0 also efficiently prevented the hypothermia generated by the injection of 100 #g 
LPS. Finally, pretreatment with a single injection of 1,000 U Ibl0 completely prevented the 
mortality consecutive to the challenge with 500 #g LPS, a dose that was lethal in 50% of 
the control mice. We conclude that Ib l0 inhibits in vivo TNF secretion and protects against 
the lethality of endotoxin in a murine model of septic shock. 
E ndotoxin (LPS) from gram-negative bacteria is a major causative agent in the pathogenesis of septic shock (1). 
A shock-like state can indeed be induced experimentally b  
a single injection of LPS into animals. These toxic effects of 
LPS are mostly related to macrophage activation leading to 
the release of multiple inflammatory mediators. Among these 
mediators, TNF appears to play a crucial role, as indicated 
by the prevention of LPS toxicity by the administration of 
neutralizing anti-TNF antibodies (2-5). 
Ib l0 is a recently described cytokine that efficiently blocks 
the in vitro production of TNF as well as of other cytokines 
by LPS-activated monocytes/maerophages (6-8). Ibl0 might 
therefore be an efficient agent o downregulate LPS toxicity 
in vivo. To test this hypothesis, we analyzed the effects of 
IL-10 administration before LPS challenge in mice, focusing 
on the systemic release of TNF, hypothermia, nd lethality. 
Materials and Methods 
Animals. 10-15-wk-old BALB/c mice were purchased from the 
KUL Proef Dieren Centrum (Leuven, Belgium). 
Reagents. LPS from Esche6chia coli (serotype O55:B5) was pur- 
chased from Sigma Chemical Co. (St. Louis, MO). The JES5-2A5 
mAb, a neutralizing rat anti-mouse Ibl0 IgG1 mAb, was kindly 
given by Tim Mosmann (Department of Immunology, University 
1 C. G6rard and C. Bruyns contributed qually to this study. 
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of Alberta, Edmonton, Canada) (9). The LO-DNP mAb, a rat IgG1 
antibody used as control, was a kind gift from H. Bazin (Ex- 
perimental Immunology Unit, Universit6 Catholique de Louvain, 
Brussels, Belgium). 
Mouse Recombinant 1I.,10: Cloning and Expression. Specific oli- 
gonucleotides for the murine IL-IO cDNA were synthesized ac- 
cording to its sequence (10), Restriction sites were added to their 
5' end for subcloning: HinclI/SaclI for the sense primer 5'-CTC- 
CATCATGCCTGGCTCA-Y (nucleotide 69-87) and SmaI/XhoI 
for the antisense primer 5'-TACACACTGCAGGTGTTTTAGC-Y 
(nucleotide 608-629). Total KNA was prepared from the spleen 
of mice injected with the hamster anti-CD3 mAb 145-2Cll as a 
nonspecific stimulator of cytokine transcription (11). 1 #g KNA 
was reverse transcribed using the antisense oligonudeotide (1/xg) 
as primer and 200 U Moloney-murine l ukemia virus (Mo-MuLV) 
reverse transcriptase (KT) (Promega Corp., Madison, WI) in KT 
buffer (50 mM KC1, 20 mM "Iris HC1, pH 8.3, 2.5 mM MgC12, 
0.1 mg/ml acetylated BSA, dNTPs 2.5 mM each, KNasin 20 U 
[Promega Corp.]) in a final volume of 20 #1. To this were added 
2.5 U Taq DNA polymerase, and 1 #g of each sense/antisense 
primer, in the same buffer, and in a total volume of 100 #1. A PCK 
was performed using a DNA thermal cycler (Perkin-Elmer Cetus, 
Norwalk, CT) for 35 cycles: 1 min denaturation at 94~ 2 rain 
annealing at 55~ and 3 min extension at 72~ A band with 
the 560-bp predicted size was obtained. The specificity of the 
amplified cDNA was validated by its restriction pattern. Sequencing 
was also performed following the dideoxynucleotide chain termi- 
nation method (12). Nucleotides 322, 465-468, 522, and 523 were 
different from those published (10), but the amino acids remained 
unchanged. The SaclI-XhoI restriction fragment, containing the 
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murine IL-10 cDNA, was inserted in the Harvey murine sarcoma 
virus-derived retroviral vector pCO6-HX in place of the coding 
sequence of p21 ras (see Fig. 1) (13). In this construction, called 
pTG1H-mlL10, the IL-10 cDNA is the only functional gene. A 
similar vector, with no inserted II.-10 gene, was used as negative 
(mock) control. To derive individual colonies of cells expressing 
high levels of Ibl0, pTG1H-mlL10 was cotransfected with the 
plasmid pSV2-neo, which contains the neomycin resistance gene 
used as a selectable marker. Transfection was performed in the CHO- 
K1 (Chinese hamster ovarian K1) cell line using a modified cal- 
cium phosphate method as described, except hat no carrier DNA 
was present (14). Selection for transfectants was initiated by adding 
400/~g/ml G418 (Geneticin; Gibco, Paisley, Scotland). 10 d later, 
individual resistant colonies were isolated and tested for IL-10 ex- 
pression using a specific enzyme-linked immunosorbent assay (Phar- 
mingen, San Diego). IL-10 concentrations were determined by ref- 
erence to a standard curve of recombinant IL-10 expressed in COS 
cell supernatant (470 U/ml) (Pharmingen). The supernatant col- 
lected after 24 h culture of a colony with high II.-10 level (200 U/ml) 
was concentrated to 5,000 U IL-10/ml on an ultrafiltration mem- 
brane (Amicon Corp., Danvers, MA). Control (mock) superna- 
rant from CHO-K1 cells transfected with the control plasmid and 
with pSV2-neo has been selected, collected, and concentrated simi- 
larly. The endotoxin content of the injected preparations was below 
1 ng/ml. 
Determination of Serum TNF Levels. Blood samples were ob- 
tained from individual mice by retroorbital puncture. Serum levels 
of TNF were estimated by a cytotoxicity assay on actinomycin- 
D-treated WEHI-164 clone 13 cells as previously described (15). 
Results were expressed in pg/ml in reference to the cytotoxic ac- 
tivity of a standardized (National Biological Standards Board, Hert- 
fordshire, UK) preparation ofrecombinant murine TNF expressed 
in Escherichia coli (16). This preparation had a specific biological 
activity of 2.25 • 10 s IU/mg, with 1 IU representing about 
4 pg routine TNF. We found that IL-10 was not interfering with 
this bioassay (data not shown). 
Experimental Protocol. Mice were injected intravenously with 
100 #g of LPS 30 min after an intraperitoneal dministration of 
either CHO-IL10 or mock supernatants. Serum TNF levels were 
determined 1.5, 3, and 6 h after LPS challenge, whereas rectal tem- 
perature was measured at regular intervals with a digital thermom- 
eter. In another series of experiments, we evaluated the effects of 
IL-10 on the lethality induced by a single dose of 500 #g LPS. 
Statistics. TNF levels and temperatures were compared using 
the Mann-Whitney U test. Lethality data were analyzed with the 
Fisher's exact test. 
v-rasH 
pCO6-HX O 
Ha-LTR Ha-L'rR Ha-MuSV pBR3.22 
i , 
H .~ S:: iX -~  
pTGIH-mlL10 / 
mlL-lO 1 kb 
I 1 
Figure 1. Construction of the routine IL-10 retroviral vector. Plasmid 
pTGIH-mlL10 was derived from the Harvey murine sarcoma virus (Ha- 
MuSV) cloned in pBR322 (pCO6-HX) (13). The entire coding region 
of v-ras H (SaclI-Xhol) was removed and replaced by the 560-bp fragment 
coding for the routine IL-10 cDNA. (Solid lines) Ha-MuSV sequences; (broken 
lines) pBR322. Restriction eodonucleases ites: (H) HindlII; (S) SaclI; (X) 
XhoI; (B) BamHI. (B/ack box) Coding sequences of IL-10; (open box) coding 
sequences of v-rasH; and (crosshatched boxes) Ha-MuSV LTRs. 
Table 1. Effects of Various Doses of lL-lO on the systemic 
release of TNF Induced by LPS 
TNF serum levels 
Pretreatment Challenge 1.5 h 3 h 
pg/ml 
Medium - <10 <10 
Medium LPS 5268 +_ 1118 <10 
Mock LPS 5270 _+ 1283 <10 
IL-10 (10 U) LPS 1216 _+ 469* ND 
IL-10 (100 U) LPS 1846 _+ 1295' ND 
IL-10 (1,000 U) LPS 416 _+ 70 s <10 
IL-10 (1,000 U) - <10 ND 
BALB/c mice (n = 5 in each group) were injected intraperitoneally with 
the indicated oses of IL-IO, 30 min before an intravenous injection of 
100/zg LPS. As control, mice were pretreated with either the medium 
used for culturing CHO-K1 cells, or the mock supernatant. Serum levels 
of biologically active TNF (mean + SEM) were determined 1.5 and 3 h 
after LPS challenge. 
* p <0.01, tp <0.05, and S p <0.005, as compared with mice pretreated 
either with control medium or with mock supernatant before LPS 
challenge. 
Results and Discussion 
To assess the in vivo effects of ID10 administration on LPS- 
induced TNF  release, three different doses of IL-10 (10, 100, 
or 1,000 U) were given intraperitoneally 30 min before the 
intravenous injection of 100 #g LPS. Since previous studies 
showed that TNF levels peaked 1.5 h after LPS chalhnge, 
blood samples were taken at that time (17). II:10 pretreat- 
ment resulted in a significant reduction in the amounts of 
`54  
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Figure 2. Time course of rectal temperature (mean _ SEM) in IIALt]/c 
mice (6-21 per group) injected with either medium alone (O); LPS (100 
~g i.v.) without pretreatment (0); LPS (100 #g i.v.) after pretreatment 
with 1,000 U II.~10 (V); or LPS (100 #g i.v.) after pretreatment with su- 
pernatant from mock-transfected CHO-K1 cells (V). 
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Lethality after injection of 500/~g LPS in three groups of 
BALB/c mice: (O) mice with no pretreatment (n = 15); (~7) mice 
pretreated intraperitoneally with 1,000 U I1.-10 (n = 15); (V) mice 
pretreated intraperitoneally with supernatant from mock-transfected CHO- 
K1 cells (n = 10). Two-tailedp value has been determined with the Fisher's 
exact test. 
TNF released inthe circulation after LPS challenge, as shown 
in Table I representing one out of three xperiments which 
gave similar esults. This in vivo effect of II.-10 was already 
observed with doses as low as 10 U (p <0.01 as compared 
with LPS after pretreatment with control medium). As 
1,000 U had a more pronounced and reproducible activity, 
this dose was chosen for further studies. The specificity of 
the effect of the I1-10 preparation was assessed by pretreating 
mice with a supernatant from mock-transfected CHO-K1 cells. 
As shown in Table 1, this control preparation had no effect 
on TNF release. TNF serum levels returned to baseline values 
3 h after LPS challenge in all groups of mice, indicating that 
ILl0 did not merely delay the release of TNF (Table 1). 
As a first approach to evaluate in vivo the effect of I1.10 
on LPS-induced toxicity, we monitored rectal temperature 
for 24 h after challenge with 100/~g LPS. Indeed, as previ- 
ously reported by others, LPS caused aprofound hypothermia 
which is probably related to TNF release (18). The data 
presented inFig. 2 indicate that II.-10 pretreatment fficiently 
prevented LPS-induced hypothermia (p <0.0001 at 4 h, and 
p <0.005 at 6 h, as compared either with LPS alone or LPS 
after pretreatment wi h mock superuatant), whereas control 
superuatant from mock-transfected CHO-K1 cells had no 
significant effect. A substantial variation in the recovery from 
hypothermia was seen among the animals injected with 100 
/~g LPS, either given alone or after pretreatment with mock 
supernatant. As an additional control of specificity for the 
effect observed after pretreatment with CHO-IL10 superna- 
tant, we added 1 mg of the neutralizing anti-mouse I1.10 
JES5-2A5 mAb or of a control rat IgG1 LO-DNP mAb to 
the II.-10 preparation. The anti-I1.10 completely abrogated 
the protective effect of I1.-10 on hypothermia whereas the con- 
trol rat mAb had no effect (data not shown). 
To evaluate he effect of I1.10 pretreatment o  LPS-induced 
lethality, mice were challenged with 500/~g LPS, a dose which 
is lethal within 72 h in 50% of the animals. All mice pretreated 
with 1,000 U II,10 survived the LPS injection, whereas 
pretreatment wi h supernatant from mock-transfected CHO- 
K1 cells did not modify the LPS-induced lethality (Fig. 3). 
Taken together, these data indicate that pretreatment with 
I1-10 prevents the toxicity of LPS in a murine model of en- 
dotoxin shock. The beneficial effect of I1-10 could be due 
at least in part to the reduction of TNF release. Indeed, a 
similar level of protection against LPS-induced lethality has 
been obtained by the use of neutralizing anti-TNF antibodies 
(2-5). In vitro data suggest that I1-10 might also prevent the 
release of other monocyte/macrophage-derived cytokines in- 
volved in the pathogenesis of septic shock, especially I1-1 (1, 
6, 19, 20). 
I1.-10 can therefore be added to the potential immunoin- 
tervention strategies for the prevention and/or treatment of
septic shock, which already include anti-TNF mAb (2-5), 
I1.1 receptor antagonist (21-23), differentiation factor/leu- 
kemia inhibitory factor (24), and G-CSF (25). Because of its 
deactivation effect on macrophages, I1-10 therapy might be 
of particular interest, possibly in combination with some of 
these other biological agents. 
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